Chromatin Bioscience Collaborates with Purespring Therapeutics

Chromatin Bioscience Ltd has announced a research collaboration with Purespring Therapeutics, a company specializing in precision nephrology. This collaboration aims to enhance gene therapy approaches by using Chromatin's chromatinLENS platform to develop cell-selective synthetic promoters. These promoters are crucial for precise gene expression, aligned with Purespring's strategy to preserve kidney function through targeted genetic therapies.

The collaboration focuses on improving the safety and effectiveness of gene delivery. This is achieved by integrating specifically designed promoters, crucial for controlling gene activity in specific cell types. Michael Roberts, CEO of Chromatin Bioscience, highlighted the alignment of Purespring's goals with Chromatin's mission.

This partnership marks a significant milestone for Chromatin Bioscience, broadening its presence in the gene therapy field. This venture expands Chromatin's network, highlighting their platform's applications across various therapeutic areas.